Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding, highly active Sjögren disease

  • Mean stimulated salivary flow increased from 0.4 to 1.1 mL/min among eight patients with baseline hyposalivation and available six-month data
     
  • Updated safety data across 73 Phase 2a basket study patients support the potential for outpatient administration, with no cytokine release syndrome, ICANS or treatment discontinuations due to adverse events
     

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today highlighted updated clinical, safety and translational data for AlloNK® (also known as AB-101) in combination with rituximab, presented by Guillermo J. Valenzuela, M.D., F.A.C.R., medical director of Integral Rheumatology & Immunology Specialists, in an oral session at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026) in Paris.

The presentation featured data from the first 11 patients with Sjögren disease (SjD) in Artiva’s ongoing company-sponsored Phase 2a basket trial who had at least six months of follow-up as of July 2, 2026. The study is single-arm and evaluates AlloNK plus rituximab following low-dose cyclophosphamide and fludarabine conditioning, with treatment administered intravenously in an outpatient setting.